Role of liver biopsy in management of chronic hepatitis C: A systematic review

Kelly A. Gebo, H. Franklin Herlong, Michael Torbenson, Mollie W. Jenckes, Geetanjali Chander, Khalil G. Ghanem, Samer S. El-Kamary, Mark Sulkowski, Eric B. Bass

Research output: Contribution to journalArticle

227 Citations (Scopus)

Abstract

This systematic review addresses 2 questions pertinent to the need for pretreatment liver biopsy in patients with chronic hepatitis C: how well do liver biopsy results predict treatment outcomes for chronic hepatitis C? How well do biochemical blood tests and serologic measures of fibrosis predict the biopsy findings in chronic hepatitis C? Medline and other electronic databases were searched from January 1985 to March 2002. Additional articles were sought in references of pertinent articles and recent journals and by querying experts. Articles were eligible for review if they reported original human data from a study that used virological, histological, pathologic, or clinical outcome measures. Paired reviewers assessed the quality of each eligible study and abstracted data. Studies suggested that advanced fibrosis or cirrhosis on initial liver biopsy is associated with a modestly decreased likelihood of a sustained virological response (SVR) to treatment. Also, studies relatively consistently showed that serum aminotransferases have modest value in predicting fibrosis on biopsy; that extracellular matrix tests hyaluronic acid and laminin may have value in predicting fibrosis, and that panels of tests may have the greatest value in predicting fibrosis or cirrhosis. Biochemical and serologic tests were best at predicting no or minimal fibrosis, or at predicting advanced fibrosis/cirrhosis, and were poor at predicting intermediate levels of fibrosis. Thus, evidence suggests that liver biopsy may have some usefulness in predicting efficacy of treatment in patients with chronic hepatitis C, and biochemical blood tests and serologic tests currently have only modest value in predicting fibrosis on liver biopsy.

Original languageEnglish (US)
Pages (from-to)S161-S172
JournalHepatology
Volume36
Issue number5
DOIs
StatePublished - Nov 1 2002
Externally publishedYes

Fingerprint

Chronic Hepatitis C
Fibrosis
Biopsy
Liver
Hematologic Tests
Serologic Tests
Laminin
Hyaluronic Acid
Transaminases
Liver Cirrhosis
Extracellular Matrix
Outcome Assessment (Health Care)
Databases

ASJC Scopus subject areas

  • Hepatology

Cite this

Gebo, K. A., Herlong, H. F., Torbenson, M., Jenckes, M. W., Chander, G., Ghanem, K. G., ... Bass, E. B. (2002). Role of liver biopsy in management of chronic hepatitis C: A systematic review. Hepatology, 36(5), S161-S172. https://doi.org/10.1053/jhep.2002.36989

Role of liver biopsy in management of chronic hepatitis C : A systematic review. / Gebo, Kelly A.; Herlong, H. Franklin; Torbenson, Michael; Jenckes, Mollie W.; Chander, Geetanjali; Ghanem, Khalil G.; El-Kamary, Samer S.; Sulkowski, Mark; Bass, Eric B.

In: Hepatology, Vol. 36, No. 5, 01.11.2002, p. S161-S172.

Research output: Contribution to journalArticle

Gebo, KA, Herlong, HF, Torbenson, M, Jenckes, MW, Chander, G, Ghanem, KG, El-Kamary, SS, Sulkowski, M & Bass, EB 2002, 'Role of liver biopsy in management of chronic hepatitis C: A systematic review', Hepatology, vol. 36, no. 5, pp. S161-S172. https://doi.org/10.1053/jhep.2002.36989
Gebo, Kelly A. ; Herlong, H. Franklin ; Torbenson, Michael ; Jenckes, Mollie W. ; Chander, Geetanjali ; Ghanem, Khalil G. ; El-Kamary, Samer S. ; Sulkowski, Mark ; Bass, Eric B. / Role of liver biopsy in management of chronic hepatitis C : A systematic review. In: Hepatology. 2002 ; Vol. 36, No. 5. pp. S161-S172.
@article{4bab5eda05c343aab726680ee47b731c,
title = "Role of liver biopsy in management of chronic hepatitis C: A systematic review",
abstract = "This systematic review addresses 2 questions pertinent to the need for pretreatment liver biopsy in patients with chronic hepatitis C: how well do liver biopsy results predict treatment outcomes for chronic hepatitis C? How well do biochemical blood tests and serologic measures of fibrosis predict the biopsy findings in chronic hepatitis C? Medline and other electronic databases were searched from January 1985 to March 2002. Additional articles were sought in references of pertinent articles and recent journals and by querying experts. Articles were eligible for review if they reported original human data from a study that used virological, histological, pathologic, or clinical outcome measures. Paired reviewers assessed the quality of each eligible study and abstracted data. Studies suggested that advanced fibrosis or cirrhosis on initial liver biopsy is associated with a modestly decreased likelihood of a sustained virological response (SVR) to treatment. Also, studies relatively consistently showed that serum aminotransferases have modest value in predicting fibrosis on biopsy; that extracellular matrix tests hyaluronic acid and laminin may have value in predicting fibrosis, and that panels of tests may have the greatest value in predicting fibrosis or cirrhosis. Biochemical and serologic tests were best at predicting no or minimal fibrosis, or at predicting advanced fibrosis/cirrhosis, and were poor at predicting intermediate levels of fibrosis. Thus, evidence suggests that liver biopsy may have some usefulness in predicting efficacy of treatment in patients with chronic hepatitis C, and biochemical blood tests and serologic tests currently have only modest value in predicting fibrosis on liver biopsy.",
author = "Gebo, {Kelly A.} and Herlong, {H. Franklin} and Michael Torbenson and Jenckes, {Mollie W.} and Geetanjali Chander and Ghanem, {Khalil G.} and El-Kamary, {Samer S.} and Mark Sulkowski and Bass, {Eric B.}",
year = "2002",
month = "11",
day = "1",
doi = "10.1053/jhep.2002.36989",
language = "English (US)",
volume = "36",
pages = "S161--S172",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "5",

}

TY - JOUR

T1 - Role of liver biopsy in management of chronic hepatitis C

T2 - A systematic review

AU - Gebo, Kelly A.

AU - Herlong, H. Franklin

AU - Torbenson, Michael

AU - Jenckes, Mollie W.

AU - Chander, Geetanjali

AU - Ghanem, Khalil G.

AU - El-Kamary, Samer S.

AU - Sulkowski, Mark

AU - Bass, Eric B.

PY - 2002/11/1

Y1 - 2002/11/1

N2 - This systematic review addresses 2 questions pertinent to the need for pretreatment liver biopsy in patients with chronic hepatitis C: how well do liver biopsy results predict treatment outcomes for chronic hepatitis C? How well do biochemical blood tests and serologic measures of fibrosis predict the biopsy findings in chronic hepatitis C? Medline and other electronic databases were searched from January 1985 to March 2002. Additional articles were sought in references of pertinent articles and recent journals and by querying experts. Articles were eligible for review if they reported original human data from a study that used virological, histological, pathologic, or clinical outcome measures. Paired reviewers assessed the quality of each eligible study and abstracted data. Studies suggested that advanced fibrosis or cirrhosis on initial liver biopsy is associated with a modestly decreased likelihood of a sustained virological response (SVR) to treatment. Also, studies relatively consistently showed that serum aminotransferases have modest value in predicting fibrosis on biopsy; that extracellular matrix tests hyaluronic acid and laminin may have value in predicting fibrosis, and that panels of tests may have the greatest value in predicting fibrosis or cirrhosis. Biochemical and serologic tests were best at predicting no or minimal fibrosis, or at predicting advanced fibrosis/cirrhosis, and were poor at predicting intermediate levels of fibrosis. Thus, evidence suggests that liver biopsy may have some usefulness in predicting efficacy of treatment in patients with chronic hepatitis C, and biochemical blood tests and serologic tests currently have only modest value in predicting fibrosis on liver biopsy.

AB - This systematic review addresses 2 questions pertinent to the need for pretreatment liver biopsy in patients with chronic hepatitis C: how well do liver biopsy results predict treatment outcomes for chronic hepatitis C? How well do biochemical blood tests and serologic measures of fibrosis predict the biopsy findings in chronic hepatitis C? Medline and other electronic databases were searched from January 1985 to March 2002. Additional articles were sought in references of pertinent articles and recent journals and by querying experts. Articles were eligible for review if they reported original human data from a study that used virological, histological, pathologic, or clinical outcome measures. Paired reviewers assessed the quality of each eligible study and abstracted data. Studies suggested that advanced fibrosis or cirrhosis on initial liver biopsy is associated with a modestly decreased likelihood of a sustained virological response (SVR) to treatment. Also, studies relatively consistently showed that serum aminotransferases have modest value in predicting fibrosis on biopsy; that extracellular matrix tests hyaluronic acid and laminin may have value in predicting fibrosis, and that panels of tests may have the greatest value in predicting fibrosis or cirrhosis. Biochemical and serologic tests were best at predicting no or minimal fibrosis, or at predicting advanced fibrosis/cirrhosis, and were poor at predicting intermediate levels of fibrosis. Thus, evidence suggests that liver biopsy may have some usefulness in predicting efficacy of treatment in patients with chronic hepatitis C, and biochemical blood tests and serologic tests currently have only modest value in predicting fibrosis on liver biopsy.

UR - http://www.scopus.com/inward/record.url?scp=0036829484&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036829484&partnerID=8YFLogxK

U2 - 10.1053/jhep.2002.36989

DO - 10.1053/jhep.2002.36989

M3 - Article

C2 - 12407590

AN - SCOPUS:0036829484

VL - 36

SP - S161-S172

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 5

ER -